BR0312920A - células tronco hematopoéticas e métodos de tratamento de doenças oculares neovasculares com as mesmas - Google Patents

células tronco hematopoéticas e métodos de tratamento de doenças oculares neovasculares com as mesmas

Info

Publication number
BR0312920A
BR0312920A BRPI0312920-9A BR0312920A BR0312920A BR 0312920 A BR0312920 A BR 0312920A BR 0312920 A BR0312920 A BR 0312920A BR 0312920 A BR0312920 A BR 0312920A
Authority
BR
Brazil
Prior art keywords
cells
hematopoietic stem
methods
same
stem cells
Prior art date
Application number
BRPI0312920-9A
Other languages
English (en)
Inventor
Martin Friedlander
Atsushi Otani
Karen Dasilva
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR0312920A publication Critical patent/BR0312920A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CéLULAS TRONCO HEMATOPOéTICAS E MéTODOS DE TRATAMENTO DE DOENçAS OCULARES NEOVASCULARES COM AS MESMAS Trata-se de populações de Células tronco hematopoética de linhagem negativa derivadas de medula óssea de mamífero (Lin¬ B¬HSC) que contêm células de progenitor endoteliais (EPC) capazes de formar vasos sanguíneos retineanos. Pelo menos cerca de 50% das células na população de Lin¬ B¬HSC inclui os marcadores de superfície celular para CD31 e c-kit. Até cerca de 8% das células pode incluir o marcador Sca-1, e até cerca de 4% das células pode incluir marcador F1K-1/KDR. As populações de Lin¬ B¬HSC isoladas da presente invenção são úteis para tratar doenças vasculares oculares. As populações de Lin¬ B¬HSC isoladas ue foram transfectadas com genes terapeticamente úteis também são proporcionais,as quais são úteis para entrega de genes no olho para terapia de gene baseada em célula.
BRPI0312920-9A 2002-07-25 2003-07-25 células tronco hematopoéticas e métodos de tratamento de doenças oculares neovasculares com as mesmas BR0312920A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39852202P 2002-07-25 2002-07-25
US46705103P 2003-05-02 2003-05-02
PCT/US2003/024839 WO2004010959A2 (en) 2002-07-25 2003-07-25 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Publications (1)

Publication Number Publication Date
BR0312920A true BR0312920A (pt) 2007-07-10

Family

ID=31191212

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312920-9A BR0312920A (pt) 2002-07-25 2003-07-25 células tronco hematopoéticas e métodos de tratamento de doenças oculares neovasculares com as mesmas

Country Status (17)

Country Link
US (2) US7153501B2 (pt)
EP (1) EP1542536B1 (pt)
JP (2) JP2005538742A (pt)
KR (2) KR101095287B1 (pt)
CN (1) CN1307300C (pt)
AT (1) ATE536405T1 (pt)
AU (1) AU2003259687B2 (pt)
BR (1) BR0312920A (pt)
CA (1) CA2493122C (pt)
DK (1) DK1542536T3 (pt)
ES (1) ES2376866T3 (pt)
MX (1) MXPA05000972A (pt)
PL (1) PL216193B1 (pt)
PT (1) PT1542536E (pt)
RU (1) RU2331669C2 (pt)
WO (2) WO2004010959A2 (pt)
ZA (1) ZA200500682B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US20060104962A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US20060104963A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
MXPA05011750A (es) * 2003-05-02 2006-06-06 Scripps Research Inst Celulas madre hematopoyeticas y metodos de tratamiento de enfermedades oculares neovasculares con las mismas.
WO2005042731A1 (en) * 2003-10-31 2005-05-12 Children's Medical Center Corporation Methods for purifying hematopoietic stem cells
US8282921B2 (en) 2004-08-02 2012-10-09 Paul Glidden tRNA synthetase fragments
CA2574186A1 (en) * 2004-08-13 2006-02-23 Medtronic, Inc. Isolation of endothelial progenitor cell subsets and methods for their use
JP2008512376A (ja) * 2004-09-03 2008-04-24 ザ・スクリプス・リサーチ・インステイチユート 単離された系統陰性造血幹細胞及びこれを用いた治療方法
DE102004055615A1 (de) * 2004-11-16 2006-05-18 Universitätsklinikum Hamburg-Eppendorf In vitro aus Knochenmarkstammzellen differenzierte Retina-spezifische Zellen, ihre Herstellung und Verwendung
ATE545697T1 (de) * 2005-02-24 2012-03-15 Scripps Research Inst Transfizierte myeloid-ähnliche zellen zur behandlung von frühgeborenenretinopathie und damit zusammenhängenden netzhauterkrankungen
KR101244202B1 (ko) * 2005-02-24 2013-03-18 더 스크립스 리서치 인스티튜트 허혈성 망막 조직의 혈관재형성 및 이의 스크리닝 방법
US7931891B2 (en) * 2005-02-24 2011-04-26 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
JP4734636B2 (ja) * 2005-11-02 2011-07-27 国立大学法人 鹿児島大学 免疫染色法、及び当該免疫染色法を利用した細胞の評価方法
PT1951864E (pt) 2005-11-07 2014-08-27 Amorcyte Inc Composições e métodos de reparação de lesões vasculares
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
EP2422796A3 (en) 2006-03-07 2013-03-13 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
KR100757265B1 (ko) * 2006-04-27 2007-09-10 (주) 차바이오텍 제대혈 유래 줄기 세포를 포함하는 요실금 치료용 조성물
DK2046349T3 (en) * 2006-07-12 2015-12-21 Mesoblast Inc TREATMENT OF EXCESSIVE NEOVASCULARIZATION
AU2007317789B2 (en) * 2006-11-07 2011-02-10 Shire Regenerative Medicine, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
US20100098675A1 (en) * 2008-05-30 2010-04-22 Nikolai Tankovich Methods for reducing the side effects of ophthalmic laser surgery
EP2331679B1 (en) * 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Ischemic tissue cell therapy
CA2743255C (en) 2008-12-03 2014-02-18 Andrew Pecora Infarct area perfusion-improving compositions and methods of vascular injury repair
WO2012005763A1 (en) 2010-07-06 2012-01-12 The Scripps Research Institute Use of myeloid-like progenitor cell populations to treat tumors
US9265813B2 (en) 2011-10-27 2016-02-23 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
US20150079047A1 (en) * 2012-04-16 2015-03-19 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
CA2882802C (en) 2012-08-24 2021-07-06 Riken Method for producing retinal pigment epithelial cell sheet
WO2020172854A1 (en) * 2019-02-28 2020-09-03 Shenzhen University Use of endothelial progenitor cells (epcs) in rejuvenating microvasculature, preventing aging and treating age-related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908763B1 (en) * 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
ATE265525T1 (de) * 1998-04-28 2004-05-15 Amersham Health As Verbesserung von trennungsverfahren
US6767737B1 (en) * 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US6780627B1 (en) * 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001284695A1 (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
ES2318063T3 (es) * 2001-02-23 2009-05-01 The Scripps Research Institute Polipeptidos derivados de la triptofanil arnt sintetasa utiles para la regulacion de la angiogenesis.
AU2003224712A1 (en) * 2002-03-21 2003-10-08 University Of Florida Modulating angiogenesis
US20060034767A1 (en) * 2002-07-05 2006-02-16 Roger Williams Medical Center Targeting and tracking of cells to specific organs and tissues in vivo

Also Published As

Publication number Publication date
ATE536405T1 (de) 2011-12-15
RU2331669C2 (ru) 2008-08-20
JP2005538742A (ja) 2005-12-22
DK1542536T3 (da) 2012-01-23
AU2003259687B2 (en) 2009-10-29
CA2493122A1 (en) 2004-02-05
US7153501B2 (en) 2006-12-26
ES2376866T3 (es) 2012-03-20
PL216193B1 (pl) 2014-03-31
JP2010285434A (ja) 2010-12-24
WO2004010959A3 (en) 2005-04-07
PL374868A1 (en) 2005-11-14
JP5385219B2 (ja) 2014-01-08
CA2493122C (en) 2012-11-27
MXPA05000972A (es) 2005-09-12
WO2004098499A2 (en) 2004-11-18
CN1307300C (zh) 2007-03-28
US20040197902A1 (en) 2004-10-07
EP1542536B1 (en) 2011-12-07
WO2004010959A2 (en) 2004-02-05
KR20050027132A (ko) 2005-03-17
RU2005105065A (ru) 2005-09-10
WO2004098499A3 (en) 2005-10-06
AU2003259687A1 (en) 2004-02-16
KR101095287B1 (ko) 2011-12-16
EP1542536A2 (en) 2005-06-22
EP1542536A4 (en) 2007-05-16
ZA200500682B (en) 2006-07-26
KR20110102961A (ko) 2011-09-19
CN1688196A (zh) 2005-10-26
US20070116685A1 (en) 2007-05-24
PT1542536E (pt) 2012-02-14

Similar Documents

Publication Publication Date Title
BR0312920A (pt) células tronco hematopoéticas e métodos de tratamento de doenças oculares neovasculares com as mesmas
Koc et al. Mesenchymal stem cells: heading into the clinic
Kita et al. Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane
Yang et al. VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells
Pellegrini et al. The control of epidermal stem cells (holoclones) in the treatment of massive full-thickness burns with autologous keratinocytes cultured on fibrin1
Sordi Mesenchymal stem cell homing capacity
CN102282252B (zh) 羊膜来源的贴壁细胞
Enzmann et al. Stem cells as tools in regenerative therapy for retinal degeneration
MX2019002288A (es) Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.
Marycz et al. Endurance exercise mobilizes developmentally early stem cells into peripheral blood and increases their number in bone marrow: implications for tissue regeneration
HK1040740A1 (zh) 生物工程化的組織構建物、其製備方法及其應用
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
DE69832402D1 (de) Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen
Kikuchi-Taura et al. Human umbilical cord provides a significant source of unexpanded mesenchymal stromal cells
WO2006091895A3 (en) Method for the treatment of retinopathy of prematurity and related retinopathic diseases
Lovell et al. Cardiac stem cell therapy: progress from the bench to bedside
Li et al. Cotransplantation of human umbilical cord-derived mesenchymal stem cells and umbilical cord blood-derived CD34+ cells in a rabbit model of myocardial infarction
Fierz et al. Patients with oral tumors. Part 1: Prosthetic rehabilitation following tumor resection.
Mueller et al. Osteoblastic differentiation of Wharton jelly biopsy specimens and their mesenchymal stromal cells after serum-free culture
Ma et al. Use of human placenta-derived cells in a preclinical model of tendon injury
Orbay et al. Comparison of endothelial differentiation capacities of human and rat adipose-derived stem cells
WO2006031467A3 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
Niemeyer et al. Transplantation of mesenchymal stromal cells on mineralized collagen leads to ectopic matrix synthesis in vivo independently from prior in vitro differentiation
WO2003029432A3 (en) Human mesenchymal progenitor cell
Bajada et al. Stem cells in regenerative medicine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/071 (2010.01), C12N 5/0789 (2010.01), A61K